Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region – Overview of 2022 and Outlook for 2023

Accessing the in-depth insight from the ‘Pharma Pricing and Reimbursement’ report can help you –

• Understand the latest/global outlook for pricing and market access reforms in the pharmaceutical industry such as HTA reforms.
• Understand price cuts/increases and reimbursement restrictions around the world through unique price intelligence and data.
• Identify the potential regions (Europe, Latin America, APAC and North America) and target the markets best suited to strategic focus.
• Benchmark launch sequence and P&R strategies with the risk scores for each potential country, and how they compare with events-driven risk.
• Anticipate expected changes in the market and adjust your business development strategies.

How is the ‘Pharma Pricing and Reimbursement’ report different from other reports in the market?

• The report provides a summary of Market Access Risk Scores (MARS) data and analysis of 75 countries for Q1 2023.
• It highlights the summary of POLI Indicators Data and Analysis for Q1 2023, which provides important insight into changes and updates in critical benchmark indicators such as the average launch sequence.
• It provides a list of the key issues (P&R Policy Reforms, HTA Reforms, Market Access Risk).
• The report gives a detailed analysis of the key players in this sector (e.g, Pfizer, AstraZeneca, Merck & Co, J&J, Novartis, Roche, and Sanofi) 

We recommend this valuable source of information to anyone involved in:

• Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease) / Distributors
• Pharmacies
• Parallel Trade Organisations
• Clinical Research Organisations (CROs)
• Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)
• Healthcare Organisations (Payers, HTA Bodies, Reimbursement Groups, Government Healthcare Organizations)

To Get a Snapshot of the Pharma Pricing and Reimbursement Market Report, Download a Free Report Sample

Pharma Pricing and Reimbursement Market and Market Access Risk Report Overview

The global market access risk score (MARS) has significantly increased in the first quarter of 2023 while remaining at an elevated risk level of 2.371. 2023 sees an increasing standoff between the pharma industry and the government. As governments look to address budget deficits and inflation, the pharma sector has been targeted as a profitable industry even during the COVID-19 pandemic.

The pharma pricing and reimbursement (P&R) and market access risk report provide an executive summary of healthcare expenditure and pharmaceutical sales forecasts from its Q1 2023 forecast cycle. For this quarterly update, GlobalData has updated the events risk ratings for the past 3 months captured in our qualitative measures, along with macroeconomic, political, legal environment, demographic and social structure effectiveness, technology and infrastructure, and environment risks. These factors are reflected in the quantitative measures. GlobalData has also included a look back at the key pricing and market access trends of 2022 and how they will define the outlook of the pharma industry in2023.

Global Market Access Risk Evolution 2021-2023

To get more insights into the market access risk evolution, download a free report sample

Pricing and Market Access Trends

The efforts to safeguard medicines supplies will continue, and some advanced markets are likely to offer pricing and reimbursement incentives to domestically produced medicines. Such small instances of pricing and reimbursement flexibility will be balanced by efforts to secure pharmaceutical savings in other areas.

For example, initiatives in the US include boosting the use of biosimilars (with one major health plan already announcing plans to add biosimilar Humira to its formulary), and direct government price negotiation (the first in US history) of selected Medicare medicines under the Inflation Reduction Act.

2023 will continue to see price hikes in response to the ongoing drug shortages due to the Russo-Ukrainian conflict, rising inflation rates, and increased cost of manufacturing. Countries such as Turkey, Greece, and Germany have already begun placing measures to incentive generics or apply downward pressure on the prices of branded medicines.

To know more about pricing and market access trends, download a free report sample

Pharma Pricing and Reimbursement and Market Access Risk - Regional Overview

The key regions considered for pharma pricing and reimbursement and market access risk are Latin America, North America, Europe, Asia-Pacific, and Middle East & Africa.

Latin America: Latin America’s improved market access was the result of some countries lifting price caps and applying changes to reimbursement mechanisms in 2022. Although these markets are maturing, the regulations put in place also tackle inflationary pressure and shortages brought about due to the war in Ukraine.

North America: In the US, pressure to control prescription drug prices has resulted in the passing of the Inflation Reduction Act, marking the first time the federal government could negotiate prices. However, in Canada, the passing of the Patented Medicine Prices Review Board (PMPRB) reforms and their ongoing effects have caused concerns over drug availability.

Europe: Many European markets in 2022 have applied significant pressure to the pharma industry in the form of cost containment measures, leading the industry to question the strength of key markets such as the UK and Germany.

Asia-Pacific: The Asia-Pacific markets continued to face challenges around pricing pressure, inflationary pressure, and drug shortages. Except for China’s expansion of essential pediatric medicine, 2022 was marked by key adjustments in the form of price controls and prolonged discussion over Japan’s pricing reform, including highly negative new “off year” price reductions.

Middle East & Africa: The Middle East & African markets saw significant changes to pricing strategies in 2022. Price hikes, reimbursement expansions, and steep changes to healthcare budgets all looked to aid market conditions against rising import costs and inflation.

For more regional insights on pharma pricing and reimbursement and market access risk, download a free report sample

Key Positive and Negative Market Access Events (October 2022 to December 2022)

Some of the key events with a positive effect on market access are as follows:

• Slovakia’s major P&R reforms see the introduction of a new cost-effectiveness threshold for orphan drugs and advanced therapies
• Belarusian MoH imposes moratorium on price increases for domestic medicines, medical devices, and health services

Some of the key events with a negative effect on market access are as follows:

• Greek MoH Bill sees burden shift from clawbacks to rebates
• Germany’s Ambulatory Oncology Drug Delivery System under scrutiny, as pharmacists question new discount rates on popular biosimilars

To know more about effect of key events on market access event risk ratings, download a free report sample

Segments Covered in the Report

Pharma Pricing and Reimbursement and Market Access Regional Outlook (2022 and 2023)

• Latin America
• North America
• Europe
• Asia-Pacific
• Middle East & Africa

Scope

Global coverage of key P&R and health policy reforms, pricing trends, and more.

Reasons to Buy

Global outlook for market access and pricing & reimbursement (P&R) in the pharmaceutical industry, including key trends that are driving opportunities and risk. The report includes our annual outlook for 2023 on the P&R and HTA policy reform environment and how that is driving GlobalData’s unique market access risk scores (MARS) which provide a quantitative framework for pricing/market access professionals to assess risk and opportunities around the world.